Rottapharm Biotech

Rottapharm Biotech is a research company dedicated to the discovery and development of innovative drugs. Operating with a mixed business model, the company focuses on both internal product development and external partnerships, including active participation or strategic investments in biotech companies and university spin-offs. This approach allows Rottapharm Biotech to leverage its expertise in medicinal and computational chemistry, biologics, and advanced therapies to advance its proprietary pipeline and collaborate on innovative projects. The company's investment strategy encompasses direct participation in small biotech companies, holdings, and venture funds as shareholders, directors, and scientific/technical development teams. Additionally, Rottapharm Biotech acts as a financial investor in biotech and medtech venture funds and companies, demonstrating its commitment to fostering innovation in the healthcare sector. This diversified approach enables the company to support a wide range of projects, from early-stage research to advanced clinical trials. With over 50 years of experience in managing both an R&D pipeline and a portfolio of marketed products, Rottapharm Biotech has developed significant expertise in various therapeutic areas, including rheumatology, pain and inflammation, immunology, and immuno-oncology. The company's scientists have gained extensive experience in drug discovery and development, encompassing new target validation, pharmacological and pharmacokinetic characterization of new drug candidates, original formulations, and the design of innovative clinical trials. This expertise positions Rottapharm Biotech as a key player in advancing healthcare solutions through strategic investments and partnerships.

Innovative drug discovery projects, Biotech and medtech ventures, University spin-offs, Advanced cell and gene therapies, Early to late-stage clinical trials, Global market potential, Strong scientific and technical development teams, Collaborative partnerships with pharmaceutical companies, Financial investments in biotech and medtech venture funds, Operational involvement in biotech and medtech projects